BioCentury
ARTICLE | Clinical News

Intra-Cellular begins Phase III trial of ITI-214 in PD

December 1, 2017 9:39 PM UTC

In October, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) began the Phase I/II ITI-214-105 trial of ITI-214 to treat idiopathic Parkinson's disease.

The double-blind, U.S. trial will evaluate once-daily oral doses of 1, 3 or 10 mg ITI-214 in about 24 PD patients for 7 days vs. placebo. The primary endpoint is safety and the secondary endpoints will assess pharmacokinetics...

BCIQ Company Profiles

Intra-Cellular Therapies Inc.

BCIQ Target Profiles

Phosphodiesterase-1 (PDE-1)